Effect of Caldine® on Renal Function in Balanced Hypertension

Terminated

• Conditions: Hypertension
• Interventions: Drug: Lacidipine; Drug: Diuretics; Drug: antihypertensive drugs; Drug: alpha blockers; Drug: Angiotensin-Converting Enzyme Inhibitors; Drug: beta blockers

• Registration Number: NCT02240641
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The study aimed at comparing the evolution of renal function in patients showing a hypertension treated by various therapeutic strategies.

Due to the contract research organisation (CRO) decision in September 2000, the database was locked and not accessible for Boehringer Ingelheim France. Consequently it was decided to stop the study and not proceed to the analysis. Thus, only safety data were processed in the safety database.

Detailed Description

Not available

Study Timeline

• Study Start: 1998-05
• Primary Completion: 2000-09
• Study First Submitted: 2014-08-28
• Status Verified: 2014-09
• Study First Submitted QC: 2014-09-15
• Last Update Submitted: 2014-09-15
• Study First Posted: 2014-09-16
• Last Update Posted: 2014-09-16

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 5417

Inclusion Criteria

• patients with hypertension requiring treatment

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
hypertension treatment strategies	alpha blockers	-
hypertension treatment strategies	Angiotensin-Converting Enzyme Inhibitors	-
hypertension treatment strategies	Diuretics	-
hypertension treatment strategies	beta blockers	-
hypertension treatment strategies	antihypertensive drugs	-
hypertension treatment strategies	Lacidipine	-

Primary Outcome Measures

Name	Time	Method
Number of patients with adverse events	up to two years